In today’s recent session, 1.43 million shares of the Wave Life Sciences Ltd (NASDAQ:WVE) have been traded, and its beta is -1.05. Most recently the company’s share price was $9.89, and it changed around $0.45 or 4.75% from the last close, which brings the market valuation of the company to $1.52B. WVE at last check was trading at a discount to its 52-week high of $16.74, offering almost -69.26% off that amount. The share price’s 52-week low was $4.25, which indicates that the recent value has risen by an impressive 57.03% since then. We note from Wave Life Sciences Ltd’s average daily trading volume that its 10-day average is 0.92 million shares, with the 3-month average coming to 930.46K.
Wave Life Sciences Ltd stock received a consensus recommendation rating of Buy, based on a mean score of 1.18. If we narrow it down even further, the data shows that 0 out of 11 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended WVE as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Wave Life Sciences Ltd is expected to report earnings per share of -0.25 for the current quarter.
Wave Life Sciences Ltd (NASDAQ:WVE) trade information
Instantly WVE has been showing a green trend so far today with a performance of 4.75% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 10.91 on recent trading dayincreased the stock’s daily price by 9.35%. The company’s shares are currently down -20.06% year-to-date, but still down -1.51% over the last five days. On the other hand, Wave Life Sciences Ltd (NASDAQ:WVE) is -4.55% down in the 30-day period. We can see from the shorts that 8.34 million shares have been sold at a short interest cover period of 7.26 day(s).
The consensus price target as assigned by Wall Street analysts is $22, which translates to bulls needing to increase their stock price by 55.05% from its current value. Analyst projections state that WVE is forecast to be at a low of $15 and a high of $36.
Wave Life Sciences Ltd (WVE) estimates and forecasts
The year-over-year growth rate is expected to be -33.82%, down from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 11.28M in revenue for the current quarter. 9 analysts expect Wave Life Sciences Ltd to make 14.28M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 12.54M and 19.69M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -10.06%. Forecasts for the next quarter put sales growth at -27.50%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 34.27%. Wave Life Sciences Ltd earnings are expected to increase by -36.93% in 2025, but the outlook is positive 34.49% per year for the next five years.
Wave Life Sciences Ltd (NASDAQ:WVE)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 16.53% of Wave Life Sciences Ltd shares, and 83.49% of them are in the hands of institutional investors. The stock currently has a share float of 100.03%. Wave Life Sciences Ltd stock is held by 243.0 institutions, with RA CAPITAL MANAGEMENT, L.P. being the largest institutional investor. By 2024-06-30, it held 14.0527% of the shares, which is about 18.2 million shares worth $90.83 million.
MAVERICK CAPITAL LTD, with 5.9211% or 7.67 million shares worth $38.27 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Russell 2000 ETF and PRIMECAP Odyssey Aggressive Growth Fund were the top two Mutual Funds as of Jan 31, 2025. The former held 2.49 shares worth $24.97 million, making up 1.62% of all outstanding shares. On the other hand, PRIMECAP Odyssey Aggressive Growth Fund held roughly 2.45 shares worth around $24.55 million, which represents about 1.60% of the total shares outstanding.
